A Ferroptosis-Related Gene Signature Identified as a Novel Prognostic Biomarker for Colon Cancer.
colon cancer
ferroptosis
gene signature
outcome risk nomogram
prognostic biomarker
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
04
2021
accepted:
09
06
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
Colon cancer (CC) is a common gastrointestinal malignant tumor with high heterogeneity in clinical behavior and response to treatment, making individualized survival prediction challenging. Ferroptosis is a newly discovered iron-dependent cell death that plays a critical role in cancer biology. Therefore, identifying a prognostic biomarker with ferroptosis-related genes provides a new strategy to guide precise clinical decision-making in CC patients. Alteration in the expression profile of ferroptosis-related genes was initially screened in GSE39582 dataset involving 585 CC patients. Univariate Cox regression analysis and LASSO-penalized Cox regression analysis were combined to further identify a novel ferroptosis-related gene signature for overall survival prediction. The prognostic performance of the signature was validated in the GSE17536 dataset by Kaplan-Meier survival curve and time-dependent ROC curve analyses. Functional annotation of the signature was explored by integrating GO and KEGG enrichment analysis, GSEA analysis and ssGSEA analysis. Furthermore, an outcome risk nomogram was constructed considering both the gene signature and the clinicopathological features. The prognostic signature biomarker composed of 9 ferroptosis-related genes accurately discriminated high-risk and low-risk patients with CC in both the training and validation datasets. The signature was tightly linked to clinicopathological features and possessed powerful predictive ability for distinct clinical subgroups. Furthermore, the risk score was confirmed to be an independent prognostic factor for CC patients by multivariate Cox regression analysis ( The novel ferroptosis-related gene signature biomarker can be utilized for predicting individualized prognosis, optimizing survival risk assessment and facilitating personalized management of CC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Colon cancer (CC) is a common gastrointestinal malignant tumor with high heterogeneity in clinical behavior and response to treatment, making individualized survival prediction challenging. Ferroptosis is a newly discovered iron-dependent cell death that plays a critical role in cancer biology. Therefore, identifying a prognostic biomarker with ferroptosis-related genes provides a new strategy to guide precise clinical decision-making in CC patients.
METHODS
METHODS
Alteration in the expression profile of ferroptosis-related genes was initially screened in GSE39582 dataset involving 585 CC patients. Univariate Cox regression analysis and LASSO-penalized Cox regression analysis were combined to further identify a novel ferroptosis-related gene signature for overall survival prediction. The prognostic performance of the signature was validated in the GSE17536 dataset by Kaplan-Meier survival curve and time-dependent ROC curve analyses. Functional annotation of the signature was explored by integrating GO and KEGG enrichment analysis, GSEA analysis and ssGSEA analysis. Furthermore, an outcome risk nomogram was constructed considering both the gene signature and the clinicopathological features.
RESULTS
RESULTS
The prognostic signature biomarker composed of 9 ferroptosis-related genes accurately discriminated high-risk and low-risk patients with CC in both the training and validation datasets. The signature was tightly linked to clinicopathological features and possessed powerful predictive ability for distinct clinical subgroups. Furthermore, the risk score was confirmed to be an independent prognostic factor for CC patients by multivariate Cox regression analysis (
CONCLUSION
CONCLUSIONS
The novel ferroptosis-related gene signature biomarker can be utilized for predicting individualized prognosis, optimizing survival risk assessment and facilitating personalized management of CC patients.
Identifiants
pubmed: 34276794
doi: 10.3389/fgene.2021.692426
pmc: PMC8280527
doi:
Types de publication
Journal Article
Langues
eng
Pagination
692426Informations de copyright
Copyright © 2021 Qi, Wang, Lin, Yan, Zuo, Chen and Shen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Transl Med. 2020 Aug;10(4):e153
pubmed: 32898321
BMC Med Genomics. 2021 Jan 6;14(1):8
pubmed: 33407456
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Front Cell Dev Biol. 2020 Jul 09;8:538
pubmed: 32733879
Cell Metab. 2019 Jul 2;30(1):14-15
pubmed: 31269423
Cancer Cell Int. 2020 Oct 12;20:503
pubmed: 33061855
Cell Death Differ. 2020 Feb;27(2):662-675
pubmed: 31273299
Front Cell Dev Biol. 2020 Oct 07;8:590226
pubmed: 33117818
Aging (Albany NY). 2020 Jul 20;12(14):14933-14948
pubmed: 32688345
Curr Biol. 2020 Nov 2;30(21):R1292-R1297
pubmed: 33142092
Int J Biol Sci. 2020 Jul 6;16(13):2430-2441
pubmed: 32760210
Onco Targets Ther. 2019 Dec 19;12:11291-11304
pubmed: 31908494
Comput Math Methods Med. 2013;2013:909525
pubmed: 23401724
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Eur J Pharm Sci. 2020 Sep 1;152:105450
pubmed: 32621966
Front Cell Dev Biol. 2020 Sep 17;8:586578
pubmed: 33043019
Redox Biol. 2017 Aug;12:558-570
pubmed: 28384611
BMJ Open Gastroenterol. 2019 Aug 24;6(1):e000313
pubmed: 31523441
Front Pharmacol. 2018 Nov 22;9:1371
pubmed: 30524291
Front Oncol. 2020 Oct 30;10:535985
pubmed: 33194594
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Redox Biol. 2020 May;32:101483
pubmed: 32169822
Oncol Lett. 2020 Jan;19(1):763-770
pubmed: 31897192
Database (Oxford). 2020 Jan 1;2020:
pubmed: 32219413
Cell Rep. 2019 Feb 5;26(6):1544-1556.e8
pubmed: 30726737
Free Radic Biol Med. 2019 Mar;133:144-152
pubmed: 30219704
J Cell Mol Med. 2020 Feb;24(3):2342-2355
pubmed: 31883309
Ann Transl Med. 2017 May;5(10):211
pubmed: 28603726
Cell Death Dis. 2020 Nov 17;11(11):988
pubmed: 33203867
Front Genet. 2020 Dec 18;11:614888
pubmed: 33391356
Anim Cells Syst (Seoul). 2018 Aug 30;22(5):334-340
pubmed: 30460115
Front Genet. 2020 Oct 06;11:907
pubmed: 33133126
Nature. 2019 May;569(7755):270-274
pubmed: 31043744
Cancers (Basel). 2019 Feb 01;11(2):
pubmed: 30717315
World J Gastroenterol. 2018 Sep 14;24(34):3834-3848
pubmed: 30228778
Cell. 2017 Oct 5;171(2):273-285
pubmed: 28985560
Nat Rev Cancer. 2019 Jul;19(7):405-414
pubmed: 31101865
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
ANZ J Surg. 2018 Mar;88(3):E114-E117
pubmed: 27618786
Nature. 2015 Apr 2;520(7545):57-62
pubmed: 25799988
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Cell Int. 2020 Dec 7;20(1):587
pubmed: 33372599
Gastroenterology. 2010 Mar;138(3):958-68
pubmed: 19914252
Clin Colorectal Cancer. 2016 Mar;15(1):1-6
pubmed: 26541320
J Cell Mol Med. 2019 Aug;23(8):4900-4912
pubmed: 31232522